Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2379]

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first...

Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC ( Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia )

Updates in prostate cancer from ESMO 2022

Prof Eleni Efstathiou, Prof Gerhardt Attard and Prof Boris Hadaschik

Updates in prostate cancer from ESMO 2022 ( Prof Eleni Efstathiou, Prof Gerhardt Attard and Prof Boris Hadaschik )

Latest in mRCC from ESMO 2022

Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane...

Latest in mRCC from ESMO 2022 ( Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane Oudard )

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike...

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell...

Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy ( Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA )

A new era of early cancer detection with blood test may change cancer screening...

Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA

A new era of early cancer detection with blood test may change cancer screening paradigms ( Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA )

Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for...

Dr Silvia Novello - University of Turin, Turin, Italy

Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squamous NSCLC ( Dr Silvia Novello - University of Turin, Turin, Italy )

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

Lenvatinib remains standard of care for first-line therapy in advanced...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC...

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

Lasofoxifene shows promise for women with ESR1-mutated mBC

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...

Lasofoxifene shows promise for women with ESR1-mutated mBC ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

New data presented at ESMO for multi-cancer early detection

Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences

New data presented at ESMO for multi-cancer early detection ( Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences )

More from ecancer